New study suggests early COVID-19 strain spread from bats by wildlife trade
Above: Nexstar Media Wire video on the differences between COVID, RSV, strep and the flu.
SAN DIEGO (FOX 5/KUSI) — A recent study from an international team of researchers, including those from UC San Diego's School of Medicine, gives new credence to the theory that the COVID-19 pandemic spread naturally by way of wild mammal trade, as opposed to a lab leak.
The study, which was published in the science journal Cell on Wednesday, examined the evolution of the COVID-19 virus — SARS-CoV-2 — and compared it to a coronavirus behind an earlier outbreak, the 2002 SARS pandemic.
Using genome sequencing to map the histories of these and more than 250 coronaviruses, the scientists found a number parallels in the evolution of the viruses behind SARS and COVID that suggest the two shared a similar mode of dispersal.
Scripps Health announces extension of contract with Anthem Blue Cross
These findings, in their view, dispute the contested theory that COVID originated from a lab leak, even as the Trump administration and Congressional Republicans have ratcheted up promotion of supposition in recent months.
The ancestors of both viruses, the study says, had circulated in horseshoe bats across much of China and other countries in southeast Asia for millennia, mutating as it interacted with other coronaviruses inside the cells of its host.
This genetic mixing, which is called recombination, creates new variations of the virus, each more potent until it reaches the point where it can become a human pathogen.
The closest ancestor identified by the study to SARS and COVID reached that tipping point only a few years before it was reported by humans — about one to two years before SARS was first detected in Guangdong Province and five to seven years before COVID emerged in Wuhan.
However, the distance between the origin of this viral ancestor and where the pandemics began was too far to have been carried just by bats. Instead, the study says these viruses spilled over into other wild animals, which were unwittingly carried hundreds of miles by traders.
The consensus among researchers of the earlier SARS pandemic has generally agreed this is how the virus reached Guangdong relatively quickly, most likely having hitched a ride to animals like palm civets or raccoon dogs commonly traded for their fur and meat.
That patten of zoonotic spread, the new study argues, bolsters the plausibility that SARS-CoV2 reached Wuhan from southwest China in the same manner.
'For more than two decades the scientific community has concluded that the live-wildlife trade was how those hundreds of miles were covered,' said Dr. Michael Worobey, the head of the Department of Ecology and Evolutionary Biology at the University of Arizona who served as a co-senior author on the study. 'We're seeing exactly the same pattern with SARS-CoV-2.'
The researchers point to an earlier study they conducted that traced human transmission of COVID-19 back to the Huanan Seafood Market in Wuhan, where many wild mammals are sold by traders, as further evidence for natural zoonotic spillover.
'At the outset of the COVID-19 pandemic, there was a concern that the distance between Wuhan and the bat virus reservoir was too extreme for a zoonotic origin,' said Dr. Joel Wertheim, a professor of medicine at UCSD School of Medicine's Division of Infectious Diseases and Global Public Health and a co-senior author of the study.
Lawsuit filed against Aladdin Mediterranean Café amid ongoing salmonella investigation
'This paper shows that it isn't unusual and is, in fact, extremely similar to the emergence of SARS-CoV-1 in 2002,' he continued.
That said, proponents of the lab leak theory have pointed to this distance as proof of their explanation of COVID's early spread, arguing it must have been human intervention in the form of scientists that transported the coronavirus from southwest China to Wuhan.
However, no evidence has been provided that an earlier strain virus was in fact at the the Wuhan Institute of Virology, the lab at the center of the theory, before the pandemic.
While researchers concede the debate on COVID's origins may in all likelihood remain unsettled, the study's authors say their findings remain notable, giving researchers additional insight into a possible future coronavirus outbreak.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
For the latest news, weather, sports, and streaming video, head to FOX 5 San Diego & KUSI News.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Newsweek
an hour ago
- Newsweek
Marjorie Taylor Greene Fumes Over Vaccine Approval: 'Not MAHA at All'
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Marjorie Taylor Greene has spoken out against a new COVID-19 vaccine being approved in the United States, saying the move is "not MAHA at all." Why It Matters Health Secretary Robert F. Kennedy Jr. is facing repeated backlash for some of his positions on health and medicine, including from people who would ordinarily support him. In May, prominent members of the Make America Great Again movement, including Nicole Shanahan, Kennedy's former presidential running mate, and media personality Laura Loomer, spoke out against Kennedy Jr.'s pick for U.S. Surgeon General Casey Means. In March, Kennedy Jr. sparked anger from anti-vax activists when he called on parents to "consult with their healthcare providers to understand their options to get the MMR vaccine," with one saying he is "no different than Fauci." Marjorie Taylor Greene, R-Ga., arrives for a meeting of House Republicans in the Capitol Visitor Center on May 15, 2025. Marjorie Taylor Greene, R-Ga., arrives for a meeting of House Republicans in the Capitol Visitor Center on May 15, 2025. AP What To Know The U.S. Food and Drug Administration (FDA) gave the green light for mNEXSPIKE (mRNA-1283), Moderna's new lower-dose COVID-19 vaccine, on May 31. Greene, the U.S. representative for Georgia's 14th congressional district, shared Moderna's post about the recent approval with the caption: "Not MAHA at all!!! Unreal." Not MAHA at all!!! Unreal. — Rep. Marjorie Taylor Greene🇺🇸 (@RepMTG) June 1, 2025 She was referring to Kennedy Jr.'s movement Make America Healthy Again, whose mission is to "aggressively combat the critical health challenges facing our citizens, including the rising rates of mental health disorders, obesity, diabetes, and other chronic diseases." Newsweek has contacted the United States Department of Health and Human Services outside of office hours, via email, for comment. The new vaccine is set to be used for adults 65 or older or people between the ages of 12 and 64 with at least one or more underlying risk factor as defined by the Centers for Disease Control and Prevention (CDC). Approval for the jab is "based on results from a randomized, observer-blind, active-controlled Phase 3 clinical trial which enrolled approximately 11,400 participants aged 12 years and older," Moderna says. It comes after Kennedy Jr. announced that the CDC is no longer encouraging COVID-19 vaccines for pregnant women and healthy children, marking a shift in federal public health guidance. What People Are Saying Chief Executive Officer of Moderna Stéphane Bancel said in a statement: "The FDA approval of our third product, mNEXSPIKE, adds an important new tool to help protect people at high risk of severe disease from COVID-19. "COVID-19 remains a serious public health threat, with more than 47,000 Americans dying from the virus last year alone. We appreciate the FDA's timely review and thank the entire Moderna team for their hard work and continued commitment to public health." Kennedy Jr. said about the new CDC guidance: "I couldn't be more pleased to announce that as of today the COVID vaccine for healthy children and healthy pregnant women has been removed from the CDC recommended immunization schedule." What Happens Next The new vaccine is expected to be ready for those eligible to take it in time for the 2025-2026 respiratory virus season. You should not get mNEXSPIKE if you had a severe allergic reaction after a previous dose of either mNEXSPIKE, SPIKEVAX (an mRNA vaccine for preventing COVID-19) or any Moderna COVID-19 vaccine or to any ingredient in these vaccines, the company warns.


Business Insider
3 hours ago
- Business Insider
Moderna announces FDA approved mNEXSPIKE, new vaccine against COVID-19
Moderna (MRNA) announced that the U.S. Food and Drug Administration, FDA, has approved mNEXSPIKE, a new vaccine against COVID-19, for use in all adults 65 and older, as well as individuals aged 12-64 years with at least one or more underlying risk factor as defined by the Centers for Disease Control and Prevention. 'The FDA approval of our third product, mNEXSPIKE, adds an important new tool to help protect people at high risk of severe disease from COVID-19,' said Stephane Bancel, Chief Executive Officer of Moderna. 'COVID-19 remains a serious public health threat, with more than 47,000 Americans dying from the virus last year alone. We appreciate the FDA's timely review and thank the entire Moderna team for their hard work and continued commitment to public health.' Confident Investing Starts Here:


Business Insider
4 hours ago
- Business Insider
Regeneron price target lowered to $650 from $700 at Citi
Citi analyst Geoff Meacham lowered the firm's price target on Regeneron (REGN) to $650 from $700 and keeps a Buy rating on the shares. The company reported mixed itepekimab Phase 3 COPD results in former smokers, the analyst tells investors in a research note. The firm says that wWhile Aerify-1 met its primary endpoint in both dosing arms, Aerify-2 failed to achieve statistical significance improvement at week 52. While Aerify-1 was positive, the path to approval is unclear, contends Citi. Confident Investing Starts Here: